A comparison of the outcomes of pulmonary versus extrapulmonary extensive‐stage small cell carcinoma
Internal Medicine Journal · 2024
DOI: 10.1111/imj.16281 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Emily Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Western Sydney University, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Carcinoma, Small Cell, Lung Neoplasms. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Extrapulmonary small cell carcinomas (EPSCCs) are rare cancers, comprising 0.1–0.4% of all cancers. The scarcity of EPSCC studies has led current treatment strategies to be extrapolated from small cell lung cancer (SCLC), justified by analogous histological and clinical features.
Aims
We conducted a retrospective cohort study comparing the outcomes of extensive‐stage (ES) SCLC and EPSCC.
Methods
Patients diagnosed with ES SCLC or EPSCC between 2010 and 2020 from four hospitals in Sydney were identified. Patients who received active treatment and best supportive care were included. The primary endpoint was overall survival (OS), and secondary endpoints were progression‐free survival (PFS) and overall response rates (ORRs).
Results
Three hundred and eighty‐four patients were included (43 EPSCC vs. 340 SCLC). EPSCC were of genitourinary ( n = 15), unknown primary ( n = 13) and gastrointestinal ( n = 12) origin. Treatment modalities for EPSCC compared to SCLC included palliative chemotherapy (56% vs 73%), palliative radiotherapy (47% vs 59%) and consolidation chest radiotherapy (10% of SCLC). Overall, median OS was 6.4 versus 7 months for EPSCC versus SCLC respectively, but highest in prostate EPSCC (25.6 months). Of those who received chemotherapy (22 EPSCC vs 233 SCLC), median OS was 10.4 versus 8.4 months (HR OS 0.81, 95% confidence interval (CI): 0.5–1.31, P = 0.38); PFS was 5.4 versus 5.5 months (HR PFS 0.93, 95% CI: 0.58–1.46, P = 0.74) and ORR were 73% versus 68%.
Conclusions
EPSCC and SCLC appeared to have comparable OS and treatment outcomes. However, the wide range of OS in EPSCC highlights the need for an improved understanding of its genomics to explore alternative therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Western Sydney University, Sydney, New South Wales, Australia.
- Macarthur Cancer Therapy Centre, Campbelltown Hospital, Sydney, New South Wales, Australia.
- Liverpool Hospital, Sydney, New South Wales, Australia.
- National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
ORCID-Profile: Emily Chen, Geovanny Gandy
Zitieren
APA
Chen, E., Yip, P. Y., Tognela, A., Gandy, G., Earl, C., Tran, P., & Kok, P. S. (2024). A comparison of the outcomes of pulmonary versus extrapulmonary extensive‐stage small cell carcinoma. Internal Medicine Journal. https://doi.org/10.1111/imj.16281
Vancouver
Chen E, Yip PY, Tognela A, Gandy G, Earl C, Tran P, et al. A comparison of the outcomes of pulmonary versus extrapulmonary extensive‐stage small cell carcinoma. Internal Medicine Journal. 2024. doi:10.1111/imj.16281
BibTeX
@article{Chen2024,
author = {Chen, Emily and Yip, Po Y and Tognela, Annette and Gandy, Geovanny and Earl, Clare and Tran, Patrick and Kok, Peey-Sei},
title = {A comparison of the outcomes of pulmonary versus extrapulmonary extensive‐stage small cell carcinoma},
journal = {Internal Medicine Journal},
year = {2024},
doi = {10.1111/imj.16281}
}
EUVIMED